Summary Using an immunoradiometric assay, Cathepsin-D (Cath-D) concentrations were measured in the cytosol of 68 normal and neoplastic human ovarian tissues. Cath-D levels were higher in malignant tumours than in normal tissue samples (P <0.01) and benign tumours (P <0.01 Research on proteolytic enzymes has recently provoked considerable interest because they may be involved in the process of tumour invasion and metastatisation (Goldfarb, 1986) . Among these enzymes much attention has been focused on Cathepsin D (Cath-D), a lysosomal aspartyl endopeptidase (Barrett, 1977) , which has been found to be identical to the oestrogen induced 52% glycoprotein first described by Westley and Rochefort in MCF-7 cells (Westley & Rochefort, 1979; Morisset et al., 1986) . This Cath-D-52 K protein, secreted by human breast cancer cells, displays a mitogenic effect in vitro (Vignon et al., 1986 ) and a proteolytic effect on extracellular matrix after its autoactivation at acidic pH (Briozzo et al., 1988) . Accordingly, it could have a role in the control of the growth and spread of human breast cancer. Moreover, in breast cancer a high cytosolic concentration of Cath-D is associated with a shorter relapse-free survival (Thorpe et al., 1989; Spyratos et al., 1989) .
Research on proteolytic enzymes has recently provoked considerable interest because they may be involved in the process of tumour invasion and metastatisation (Goldfarb, 1986) . Among these enzymes much attention has been focused on Cathepsin D (Cath-D), a lysosomal aspartyl endopeptidase (Barrett, 1977) , which has been found to be identical to the oestrogen induced 52% glycoprotein first described by West- ley and Rochefort in MCF-7 cells (Westley & Rochefort, 1979; Morisset et al., 1986) . This Cath-D-52 K protein, secreted by human breast cancer cells, displays a mitogenic effect in vitro (Vignon et al., 1986 ) and a proteolytic effect on extracellular matrix after its autoactivation at acidic pH (Briozzo et al., 1988) . Accordingly, it could have a role in the control of the growth and spread of human breast cancer. Moreover, in breast cancer a high cytosolic concentration of Cath-D is associated with a shorter relapse-free survival (Thorpe et al., 1989; Spyratos et al., 1989) .
At present only few data are available on the presence of Cath-D in malignancies other than breast cancer .
In the present study, the concentrations of Cath-D were assayed by an immunoradiometric method in human ovarian cancer cytosols and correlated with other pathological and biological parameters. al., 1988, 1989 tissue. Interestingly, Cath-D levels were significantly higher in ovarian cancer than in normal ovary. Similar findings have previously been obtained when breast and endometrial cancer (Briozzo et al., 1988) and may also be an autocrine mitogen (Vignon et al., 1986) , the difference in Cath-D content might represent a biochemical characteristic reflecting a different biological aggressiveness. Our finding of high Cath-D levels in metastatic ovarian tumours support the hypothesis that Cath-D production may in some way be linked to tumour progression and invasiveness. In fact, in human breast cancer Cath-D is a powerful independent prognostic factor in predicting relapse-free survival (Thorpe et al., 1989; Spyratos et al., 1989) . The lack of correlation between Cath-D levels and other prognostic parameters such as a stage, histotype, grading and EGF-R (Bauknecht et al., 1988; Battaglia et al., 1989) could indicate that, like in human breast cancer, the prognostic value of Cath-D could be additive (Maudelonde et al., 1988; Brouillet et al., 1990) . It has also to be taken into account, however, that the tumour concentrations of Cath-D may be influenced by the proportion of stromal and inflammatory components (Imort et al., 1983) . Further immunohistochemical studies should be addressed to verify this point.
The mechanism of the mitogenic action of Cath-D is unknown. As for other proteases, Cath-D may act indirectly by releasing growth factors, such as TGF alpha, from precursors or from extracellular metrix and/or by activating growth factor receptors (Derynck et al., 1984; Lawrence et al., 1985) . However, the lack of correlation between Cath-D and EGFR suggests that the tissue binding capacity for EGF is not influenced by Cath-D content. It is well known that Cath-D levels are regulated by oestrogen in human breast cancer cells (Westley & Rochefort, 1979) and by progesterone in rat uterus (Elangovan, 1980) and human endometrium . In our series, no correlation was found between Cath-D levels and ER and PR expression. This is consistent with previous findings showing that the concentrations of Cath-D in breast and endometrial cancer are independent from receptor status (Maudelonde et al., 1988 , and that Cath-D is also constitutively produced and secreted in ER-breast cancer cells . In conclusion our data demonstrate that ovarian tumours contain Cath-D and that this protein could represent a possible prognostic marker in these tumours. This needs to be ascertained by prospective clinical trials which are now under way.
